Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

United European Gastroenterology Journal

Volumn 5, Issue 7, 2017, Pages 987-996

  Pinter, Matthias ^a,b   Weinmann, Arndt ^c   Wörns, Marcus Alexander ^c   Hucke, Florian ^a,d   Bota, Simona ^a,d   Marquardt, Jens U ^c   Duda, Dan G ^b   Jain, Rakesh K ^b   Galle, Peter R ^c   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a,d   Sieghart, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Division of Gastroenterology   (Austria)

Author keywords

angiotensin II receptor blocker; angiotensin converting enzyme inhibitor; Hepatocellular carcinoma; renin angiotensin system; sorafenib

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; RAS INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEST SUPPORTIVE CARE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; EXPERIMENTAL THERAPY; FEMALE; HEALTH CARE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 85030548706     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640617695698     Document Type: Article

References (70)

1. Torre LA, Bray F, Siegel RL, Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2. Hucke F, Sieghart W, Schoniger-Hekele M, Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program? Wien Klin Wochenschr 2011; 123: 542–551.
3. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
4. Pinter M, Trauner M, Peck-Radosavljevic M, Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open 2016; 1: e000042–e000042.
5. Dyson J, Jaques B, Chattopadyhay D, Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110–117.
6. Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
7. Bruix J, Merle P, Granito A, Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Ann Oncol 2016; 27(Suppl 2): ii140–ii140.
8. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072–2079.
9. Chae YK, Valsecchi ME, Kim J, Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011; 29: 585–593.
10. Morris ZS, Saha S, Magnuson WJ, Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer 2016; 122: 2487–2495.
11. Keizman D, Huang P, Eisenberger MA, Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 2011; 47: 1955–1961.
12. Nakai Y, Isayama H, Ijichi H, Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010; 103: 1644–1648.
13. Wilop S, von Hobe S, Crysandt M, Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 2009; 135: 1429–1435.
14. Izzedine H, Derosa L, Le Teuff G, Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015; 26: 1128–1133.
15. Januel E, Ursu R, Alkhafaji A, Impact of renin–angiotensin system blockade on clinical outcome in glioblastoma. Eur J Neurol 2015; 22: 1304–1309.
16. Menter AR, Carroll NM, Sakoda LC, Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. Epub ahead of print 20 August 2016. DOI: 10.1016/j.cllc.2016.07.008.
17. Sorich MJ, Kichenadasse G, Rowland A, Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: a pooled secondary analysis of clinical trials. Int J Cancer 2016; 138: 2293–2299.
18. Facciorusso A, Del Prete V, Crucinio N, Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol 2015; 30: 1643–1650.
19. Yoshiji H, Noguchi R, Ikenaka Y, Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011; 26: 1547–1553.
20. Yoshiji H, Noguchi R, Toyohara M, Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009; 51: 315–321.
21. Yoshiji H, Noguchi R, Namisaki T, Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol 2014; 49: 1421–1429.
22. Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698–711.
23. Tandon P, Abraldes JG, Berzigotti A, Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 2010; 53: 273–282.
24. Ager EI, Neo J, Christophi C. The renin–angiotensin system and malignancy. Carcinogenesis 2008; 29: 1675–1684.
25. George AJ, Thomas WG, Hannan RD. The renin–angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010; 10: 745–759.
26. Pinter M, Sieghart W, Reiberger T, The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma: a pilot study. Aliment Pharmacol Ther 2012; 35: 83–91.
27. Chauhan VP, Martin JD, Liu H, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013; 4: 2516–2516.
28. Bataller R, Gines P, Nicolas JM, Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149–1156.
29. Gressner AM, Weiskirchen R, Breitkopf K, Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793–d807.
30. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31: 2205–2218.
31. Yoshiji H, Kuriyama S, Yoshii J, Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745–750.
32. Watt J, Kocher HM. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoimmunology 2013; 2: e26788–e26788.
33. Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 2014; 211: 1503–1523.
34. Feig C, Jones JO, Kraman M, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 2013; 110: 20212–20217.
35. Pure E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res 2016; 4: 269–278.
36. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 2014; 16: 321–346.
37. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014; 26: 605–622.
38. Lee JI, Campbell JS. Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol 2014; 61: 432–434.
39. Chen Y, Huang Y, Reiberger T, Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014; 59: 1435–1447.
40. Moreno M, Gonzalo T, Kok RJ, Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010; 51: 942–952.
41. Jonsson JR, Clouston AD, Ando Y, Angiotensin–converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148–155.
42. Paizis G, Gilbert RE, Cooper ME, Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001; 35: 376–385.
43. Yoshiji H, Yoshii J, Ikenaka Y, Inhibition of renin–angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22–30.
44. Corey KE, Shah N, Misdraji J, The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009; 29: 748–753.
45. Rimola A, Londono MC, Guevara G, Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686–691.
46. Terui Y, Saito T, Watanabe H, Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022–1022.
47. Hoshida Y, Villanueva A, Kobayashi M, Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995–2004.
48. Hollebecque A, Cattan S, Romano O, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193–1201.
49. Pinter M, Sieghart W, Hucke F, Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949–959.
50. Sohn W, Paik YH, Cho JY, Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol 2015; 62: 1112–1121.
51. Okwan-Duodu D, Landry J, Shen XZ, Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol 2013; 305: R205–R215.
52. Egami K, Murohara T, Shimada T, Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clini Invest 2003; 112: 67–75.
53. Fujita M, Hayashi I, Yamashina S, Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26: 271–279.
54. Ohnuma Y, Toda M, Fujita M, Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 2009; 63: 136–145.
55. Otake AH, Mattar AL, Freitas HC, Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 2010; 66: 79–87.
56. Noguchi R, Yoshiji H, Kuriyama S, Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003; 9: 6038–6045.
57. Yoshiji H, Noguchi R, Kuriyama S, Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep 2005; 13: 491–495.
58. Tamaki Y, Nakade Y, Yamauchi T, Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol 2013; 48: 491–503.
59. Yanase K, Yoshiji H, Ikenaka Y, Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5–fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2007; 17: 441–446.
60. Nasr M, Selima E, Hamed O, Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharmacol 2014; 723: 267–275.
61. Yoshiji H, Kuriyama S, Kawata M, The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073–1078.
62. Yoshiji H, Kuriyama S, Noguchi R, Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 2005; 42: 687–693.
63. Yoshiji H, Kuriyama S, Noguchi R, Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2006; 15: 155–159.
64. Yoshiji H, Noguchi R, Kaji K, Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol 2010; 45: 443–450.
65. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
66. Fernandez M, Semela D, Bruix J, Angiogenesis in liver disease. J Hepatol 2009; 50: 604–620.
67. De BK, Bandyopadhyay K, Das TK, Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003; 98: 1371–1376.
68. Debernardi-Venon W, Martini S, Biasi F, AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026–1033.
69. Gonzalez-Abraldes J, Albillos A, Banares R, Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382–388.
70. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334–339.